Delving into the Latest Updates on HealZen Therapeutics Co., Ltd. with Synapse

Overview

Basic Info

Introduction

Hangzhou Hezheng Pharmaceutical Co., Ltd. is an innovative chemical small molecule drug research and development enterprise with an international vision. The company implements the purpose of "being benevolent and making righteous medicine" and is committed to the research and development of innovative drugs in the fields of tumor immunology and liver disease. In 2016, the company won the first prize of the China Innovation and Entrepreneurship Competition and the second prize of the Zhejiang Innovation and Entrepreneurship Competition (first place in the biomedical group). In 2019, the company passed the standard certification and became a standard-compliant enterprise. In the same year, the Hangzhou R&D Center was established.

Tags

Neoplasms

Hemic and Lymphatic Diseases

Immune System Diseases

Proteolysis-targeting chimeras (PROTAC)

Chemical drugs

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	9
Hemic and Lymphatic Diseases	7
Immune System Diseases	6
Infectious Diseases	1
Nervous System Diseases	1

Top 5 Drug Type	Count

Proteolysis-targeting chimeras (PROTAC)	4
Chemical drugs	3
Small molecule drug	2

Top 5 Target	Count

BTK(Tyrosine-protein kinase BTK)	3
STAT3(Signal transducer and activator of transcription 3)	2
CK1ε x PI3Kδ	1
PDL1(Programmed death-ligand 1)	1
HPK1(Mitogen-activated protein kinase kinase kinase kinase 1)	1

主要目的：评价HZ-H08905对比西达本胺治疗复发/难治性外周T细胞淋巴瘤患者的无进展生存期（PFS）（由独立评审委员会评估）。关键次要目的：评价HZ-H08905对比西达本胺治疗复发/难治性外周T细胞淋巴瘤患者总生存期（OS）。其它次要目的： 1）评价HZ-H08905对比西达本胺治疗复发/难治性外周T细胞淋巴瘤患者的其他有效性，如研究者评估的无进展生存期（PFS）、总体缓解率（ORR）、完全缓解率（CRR）、缓解持续时间（DOR）、疾病控制率（DCR）和起效时间（TTR）。 2）评价HZ-H08905对比西达本胺治疗复发/难治性外周T细胞淋巴瘤患者的安全性。

[Translation]

Primary objective: To evaluate the progression-free survival (PFS) of HZ-H08905 versus chidamide in patients with relapsed/refractory peripheral T-cell lymphoma (assessed by an independent review committee). Key secondary objectives: To evaluate the overall survival (OS) of HZ-H08905 versus chidamide in patients with relapsed/refractory peripheral T-cell lymphoma. Other secondary objectives: 1) To evaluate other effectiveness of HZ-H08905 versus chidamide in patients with relapsed/refractory peripheral T-cell lymphoma, such as investigator-assessed progression-free survival (PFS), overall response rate (ORR), complete response rate (CRR), duration of response (DOR), disease control rate (DCR), and time to response (TTR). 2) To evaluate the safety of HZ-H08905 versus chidamide in patients with relapsed/refractory peripheral T-cell lymphoma.

Start Date28 Jun 2024

Sponsor / Collaborator

HealZen Therapeutics Co., Ltd.

CTR20240471 / RecruitingPhase 1

一项评价BTK蛋白降解剂HZ-Q1070治疗复发或难治性B细胞恶性肿瘤的安全性/耐受性和药代动力学/药效动力学的I期临床研究

[Translation] A Phase I clinical study evaluating the safety/tolerability and pharmacokinetics/pharmacodynamics of the BTK protein degrader HZ-Q1070 in the treatment of relapsed or refractory B-cell malignancies

主要目的：1）评估HZ-Q1070在复发或难治性B细胞恶性肿瘤患者中的安全性/耐受性；2）确定HZ-Q1070最大耐受剂量（MTD）及II期临床推荐剂量（RP2D）。次要目的：1）评估HZ-Q1070在复发或难治性B细胞恶性肿瘤患者中的药代动力学（PK）特征和药效动力学（PD）特征；2）初步评价HZ-Q1070在复发或难治性B细胞恶性肿瘤患者的有效性。

[Translation]

Primary objectives: 1) Evaluate the safety/tolerability of HZ-Q1070 in patients with relapsed or refractory B-cell malignancies; 2) Determine the maximum tolerated dose (MTD) and recommended dose (RP2D) for Phase II clinical trials of HZ-Q1070. Secondary objectives: 1) Evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of HZ-Q1070 in patients with relapsed or refractory B-cell malignancies; 2) Preliminary evaluation of the effectiveness of HZ-Q1070 in patients with relapsed or refractory B-cell malignancies.

Start Date25 Mar 2024

Sponsor / Collaborator

Zhongke Bohai Rim (Yantai) Advanced Institute of Pharmaceutical Sciences Co., Ltd.

[+2]

CTR20213233 / Active, not recruitingPhase 1

HZ-H08905在复发或难治性非霍奇金淋巴瘤患者的安全性/耐受性及药代动力学的I期临床研究

[Translation] Phase I clinical study of the safety/tolerability and pharmacokinetics of HZ-H08905 in patients with relapsed or refractory non-Hodgkin's lymphoma

主要目的：1）评估HZ-H08905在复发或难治性非霍奇金淋巴瘤患者中的安全性/耐受性；2）确定HZ-H08905最大耐受剂量（MTD）及II期临床推荐剂量（RP2D）。次要目的：1）评估HZ-H08905在复发或难治性非霍奇金淋巴瘤患者中的药代动力学（PK）特征；2）初步评价HZ-H08905在复发或难治性非霍奇金淋巴瘤患者的有效性。

[Translation]

Primary objectives: 1) Evaluate the safety/tolerability of HZ-H08905 in patients with relapsed or refractory non-Hodgkin's lymphoma; 2) Determine the maximum tolerated dose (MTD) and recommended dose (RP2D) of HZ-H08905 for Phase II clinical trials. Secondary objectives: 1) Evaluate the pharmacokinetic (PK) characteristics of HZ-H08905 in patients with relapsed or refractory non-Hodgkin's lymphoma; 2) Preliminary evaluation of the effectiveness of HZ-H08905 in patients with relapsed or refractory non-Hodgkin's lymphoma.

Start Date29 Dec 2021

Sponsor / Collaborator

HealZen Therapeutics Co., Ltd.

100 Clinical Results associated with HealZen Therapeutics Co., Ltd.

Login to view more data

0 Patents (Medical) associated with HealZen Therapeutics Co., Ltd.

Login to view more data

1

Literatures (Medical) associated with HealZen Therapeutics Co., Ltd.

01 Jan 2023·Frontiers in pharmacology

HZ-A-018, a novel inhibitor of Bruton tyrosine kinase, exerts anti-cancer activity and sensitizes 5-FU in gastric cancer cells.

Article

Author: Zhang, Bo ; Ma, Junjie ; Liu, Danjing ; Lin, Bin ; Shen, Shuying ; Ji, Cong ; Lin, Nengming ; Yan, Youyou ; Xu, Wei ; Shen, Minmin ; Zhou, Xinglu

Gastric cancer is the third leading cause of cancer related death worldwide. Due to the complexity and heterogeneity of gastric cancer, the development of targeted drugs is somehow limited, but is urgently needed. Since the expression of Bruton tyrosine kinase (BTK) was significantly associated with the prognosis of gastric cancer patients, we aimed to determine the anti-cancer activity of HZ-A-018, which was a novel derivative of ACP-196, in gastric cancer cells. As a result, HZ-A-018 presented a stronger anti-proliferation activity than ACP-196 via the substantial suppression of AKT/S6 pathway. In addition, HZ-A-018, but not ACP-196, exerted the synergistic effects in combined treatment with 5-FU both in vitro and in vivo, without exacerbating the adverse effects of 5-FU. Mechanismly, the combination of HZ-A-018 and 5-FU remarkably reduced the expression of RRM2, which played an essential role in proliferation and drug sensitivity in gastric cancer cells. In summary, our work demonstrated the stronger anti-cancer activity of HZ-A-018 than ACP-196 in gastric cancer cells, and revealed synergistic effects of HZ-A-018 and 5-FU combination probably through the inhibition of RRM2 via AKT/S6 pathway, thereby providing a promising therapeutic strategy in gastric cancer.

100 Deals associated with HealZen Therapeutics Co., Ltd.

Login to view more data

100 Translational Medicine associated with HealZen Therapeutics Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 07 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

5

1

IND Approval

Phase 1 Clinical

1

Phase 2 Clinical

Phase 3 Clinical

1

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

HZ-H08905 ( CK1ε x PI3Kδ )	Peripheral T-Cell Lymphoma More	Phase 3
HZ-A-018 ( BTK )	Primary Central Nervous System Lymphoma More	Phase 2
HZ-Q1070 ( BTK )	B-Cell Malignant Neoplasm More	Phase 1
HZ-L105 ( Bcl-2 )	B-Cell Malignant Neoplasm More	IND Approval
HZ-R061 ( STAT3 )	Hematologic Neoplasms More	Preclinical